Hantong Medical

Hantong Medical Technology, established in 2022, is a platform-based company focused on providing interventional ultrasound solutions for vascular-related diseases. The company, headquartered in Shanghai, China, was founded by Dr. Wanjin Zhao, who also serves as the CEO. Hantong Medical operates within the therapeutic and diagnostic devices sector, developing a proprietary ultrasound energy platform that encompasses various core technologies like host systems, algorithms, catheters, and ultrasonic transducers.

The company's initial product is designed for treating hypertension through renal artery ultrasonic ablation, also known as ultrasound renal denervation (RDN). This technology has progressed to the clinical trial stage. The business model centers on the research, development, and eventual commercialization of these medical devices. Hantong Medical targets the healthcare market, providing its technology to address vascular conditions, with a significant focus on the large population affected by hypertension in China.

Since its inception, Hantong Medical has secured significant funding through multiple investment rounds. In December 2022, it completed an angel round, followed by an angel+ round in June 2023. By January 2025, the company had raised approximately $13.7 million in an early-stage VC round, bringing its total funding to date to notable levels with investments from firms such as Fortune Capital, Jifeng Ventures, and Pudong Capital. These funds are allocated to accelerate the clinical development and commercialization of its RDN technology and to support the research and development of a broader pipeline of interventional ultrasound products.

Keywords: interventional ultrasound, renal denervation, RDN, hypertension treatment, vascular diseases, medical devices, therapeutic devices, diagnostic equipment, ultrasound ablation, catheter technology, ultrasonic transducer, medtech, vascular intervention, healthcare technology, clinical trials